TD Asset Management
GENB

TD Asset Management’s Generate Biomedicines GENB Stock Holding History

TD Asset Management’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Buy
50,748
+7,882
+18% +$107K ﹤0.01% 1115
2026
Q1 		$536K Buy
+42,866
New +$523K ﹤0.01% 1165

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TD Asset Management's GENB Position: Q2 2026 in Review

TD Asset Management increased its Generate Biomedicines (GENB) stake by 18% in Q2 2026, buying an estimated $107K and bringing the position to 50,748 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

TD Asset Management first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • TD Asset Management held 50,748 shares of Generate Biomedicines worth $856K as of Q2 2026.
  • TD Asset Management bought 7,882 Generate Biomedicines shares in Q2 2026, an estimated $107K.
  • Generate Biomedicines made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1115 holding.
  • TD Asset Management first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.